Vanberra Signal

Cambridge Research & Instrumentation

Curated by Signal

Tools for In vivo imaging

Overview

CRi engages in developing in-vivo imaging systems for biomedical research. The company has proprietary platforms Nuance for multispectral imaging on brightfield and fluorescence microscopes, inForm automated image analysis software Vectra for high-throughput slide imaging and analysis and, Maestro for in-vivo optical imaging. It collaborated with Novartis and CST to understand and demonstrate the use of it imaging technology to assess biomarkers for patient selection, drug response, and molecular diagnostic development. Caliper Life Science acquired CRi in Dec 2010 and got acquired by Perkin Elmer in Sep 2011.

Key facts

Founded
1985

Contact

More on Vanberra Signal

Members only

Competitors & similar companies

More Life Sciences Technology companies
  • Omics platform for storing, analyzing, and understanding life sciences data to accelerate scientific discovery

    Life Sciences TechnologyAustin, United States
  • Developer of therapeutics for the treatment of inflammatory and rare diseases

    Life Sciences TechnologyPalo Alto, United States
  • Minimally invasive devices for continuous monitoring of glucose, sepsis, and cancer

    Life Sciences TechnologySanta Clarita, United States

About Cambridge Research & Instrumentation

What does Cambridge Research & Instrumentation do?

CRi engages in developing in-vivo imaging systems for biomedical research.

Where is Cambridge Research & Instrumentation headquartered?

Cambridge Research & Instrumentation is headquartered in Hopkinton, United States.

When was Cambridge Research & Instrumentation founded?

Cambridge Research & Instrumentation was founded in 1985.

Which sector is Cambridge Research & Instrumentation in?

Cambridge Research & Instrumentation operates in Life Sciences Technology.

Who are Cambridge Research & Instrumentation's competitors?

Companies similar to Cambridge Research & Instrumentation include GenRAIT, GEn1E, and PercuSense.